Palbociclib is indicated for-

The treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:

  • an aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or
  • fulvestrant in women with disease progression following endocrine therapy.